Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG701

—

d2442dbb-b8cf-52fa-afa0-863764c39d51

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UNFOLDED_PROTEIN_RESPONSE+0.399
  • HYPOXIA+0.396
  • NOTCH_SIGNALING+0.376
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.373
  • HEDGEHOG_SIGNALING+0.368
  • GLYCOLYSIS+0.360
  • UV_RESPONSE_UP+0.342
  • MYOGENESIS+0.321
  • APICAL_JUNCTION+0.315
  • TGF_BETA_SIGNALING+0.286

Top 10 suppressed

  • E2F_TARGETS-0.187
  • PANCREAS_BETA_CELLS-0.122
  • BILE_ACID_METABOLISM-0.115
  • PEROXISOME-0.107
  • UV_RESPONSE_DN-0.096
  • PROTEIN_SECRETION-0.087
  • HEME_METABOLISM-0.078
  • KRAS_SIGNALING_DN-0.045
  • OXIDATIVE_PHOSPHORYLATION-0.042
  • MITOTIC_SPINDLE-0.033

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1BS_4T0HPZDC
brain-umap@2
Posterior Fossa Ependymoma—0.825
2BS_4C4MZ4NT
brain-umap@2
pilocytic astrocytoma—0.818
3TCGA-85-8481-01A-11R-2326-07
lung-landscapes@6
—cohortSQ10.816
4BS_196BBNEJ
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.814
5SJEPD001508_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.792
6BS_N1E0H8YQ
brain-umap@2
low-grade glioma—0.791
7BS_QWTE1CWR
brain-umap@2
high-grade glioma—0.788
8BS_1QXEC43H
medullo-epn-umap@date-based
MedMedulloblastoma0.782
9BS_RXN5T5YT
brain-umap@2
Diffuse intrinsic pontine glioma—0.780
10BS_4T0HPZDC
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.777

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UNFOLDED_PROTEIN_RESPONSE0.399Idelalisib— uncovered
HYPOXIA0.396Idelalisib— uncovered
NOTCH_SIGNALING0.376Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.373Inavolisib— uncovered
HEDGEHOG_SIGNALING0.368Inavolisib— uncovered
GLYCOLYSIS0.360Inavolisib— uncovered
UV_RESPONSE_UP0.342Idelalisib— uncovered
MYOGENESIS0.321Inavolisib— uncovered
APICAL_JUNCTION0.315Inavolisib— uncovered
TGF_BETA_SIGNALING0.286Inavolisib— uncovered
MYC_TARGETS_V20.266Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.255Inavolisib— uncovered
MTORC1_SIGNALING0.251Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.243Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.228Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.228Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.212Remibrutinib— uncovered
ANGIOGENESIS0.198Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.196Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.188Inavolisib— uncovered